The FDA Approves Litfulo® (Ritlecitinib) for the Treatment of Severe Alopecia Areata in Adolescents and Adults

September 2023 in “ Medicina Estética Revista Científica de la Sociedad Española de Medicina Estética (SEME) ”

Xavier Álvarez Suriaca

ritlecitinib alopecia areata JAK3/TEC kinases immune response hair follicle inflammation autoimmune disease Litfulo FDA-approved treatment hair loss immune system

Studysummary This research reported that the FDA approved Litfulo® (ritlecitinib) as the first oral treatment for severe alopecia areata in adolescents over 12 years old, with 23% of treated patients showing significant hair regrowth in clinical trials compared to 1.6% with placebo.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on seme.org →

Discuss this study in the Community →

Research cited in this study

6 / 6 results

research A Plain Language Summary on Ritlecitinib Treatment for Adults and Adolescents with Alopecia Areata

7 citations , July 2023 in “Immunotherapy”

Ritlecitinib works well and is safe for treating alopecia areata.

Systematic Review of Newer Agents for the Management of Alopecia Areata in Adults: Janus Kinase Inhibitors, Biologics and Phosphodiesterase-4 Inhibitors

research Systematic Review of Newer Agents for the Management of Alopecia Areata in Adults: Janus Kinase Inhibitors, Biologics and Phosphodiesterase-4 Inhibitors

12 citations , December 2022 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

This review suggests that oral Janus kinase inhibitors are a promising treatment for alopecia areata in adults, showing significant hair regrowth with fewer side effects than conventional treatments, while PDE-4 inhibitors and biologics show limited efficacy.

research A Retrospective Study on Alopecia Areata in Children: Clinical Characteristics and Treatment Choices

1 citations , January 2021 in “Skin appendage disorders”

This study observed that alopecia areata in children often presents as mild scalp patches, with the majority showing some hair regrowth following treatment, particularly when using potent topical steroids, which were most commonly prescribed in the reviewed cases.

The FDA Approves Litfulo® (Ritlecitinib) for the Treatment of Severe Alopecia Areata in Adolescents and Adults

Research cited in this study

research A Plain Language Summary on Ritlecitinib Treatment for Adults and Adolescents with Alopecia Areata

research Systematic Review of Newer Agents for the Management of Alopecia Areata in Adults: Janus Kinase Inhibitors, Biologics and Phosphodiesterase-4 Inhibitors

research A Retrospective Study on Alopecia Areata in Children: Clinical Characteristics and Treatment Choices

research Prevalence of Pediatric Alopecia Areata Among 572,617 Dermatology Patients

research The Autoimmune Basis of Alopecia Areata: A Comprehensive Review

research Alopecia Areata: A Tissue-Specific Autoimmune Disease of the Hair Follicle